Quest Diagnostics Incorporated (DGX): What the Financials Tell Us?

Quest Diagnostics Incorporated (NYSE:DGX) saw an upside of 0.09% to close Tuesday at $140.48 after adding $0.12 on the day. The 5-day average trading volume is 1,256,440 shares of the company’s common stock. It has gained $145.20 in the past week. An average of 1,331,005 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,198,212.

DGX’s 1-month performance is -8.72% or -$14.46 on its low of $139.66 reached on 10/11/21. The company’s shares have touched a 52-week low of $113.36 and high of $160.56, with the stock’s rally to the 52-week high happening on 09/09/21. YTD, DGX has achieved 17.88% or $21.31. However, the current price is down -12.51%% from the 52-week high price.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Insider Transactions

On Jul 29, 76 days have gone by since the last insider trading activity for Quest Diagnostics Incorporated (DGX). RUSCKOWSKI STEPHEN H (Chairman, CEO and President) most recently sold 9,493 shares at $140.87 per share on Jul 29. This transaction cost the insider $1,337,251. Chairman, CEO and President, RUSCKOWSKI STEPHEN H, sold 139,751 shares at a price of $140.14 on Jul 28. Then, on Jul 27, Chairman, CEO and President RUSCKOWSKI STEPHEN H sold 32,788 shares at a price of $140.01 per share. This transaction amounted to $4,590,550.

Valuation Metrics

The company’s PE ratio for the last five years has touched a high of 23.60 and a low of 7.869. DGX stock has a beta of 1.03. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 1.57 while the price-to-book (PB) in the most recent quarter is 2.98, with the price to cash flow ratio at 9.31.

Quest Diagnostics Incorporated pays an annual dividend of $2.48 per share. Its dividend yield is 1.77% and the payout ratio is 13.50%. DGX paid $0.62 a share compared with prior rate of $0.62, down 0.0% from last year’s. The company has boosted its dividend for the last 1 consecutive years with the latest dividend increase of $0.06 reported on Thursday February 4 2021. Measured over the last 3 years, the Dividend has been growing by 22.78% yearly.

It is projected that Quest Diagnostics Incorporated’s next ex-dividend date will be on 18-Jan. DGX is expected to distribute $0.62 as its next dividend.

Quest Diagnostics Incorporated’s quick ratio for the period ended June 29 was 1.30, with the current ratio over the same period at 1.40 meaning that DGX stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.68, while the total debt to equity was 0.68. In terms of profitability, the gross margin trailing 12 months is 41.70%. The trailing 12-month EBITDA margin is 26.13% while for the period ending June 29; Quest Diagnostics Incorporated’s operating margin was 24.50%. The firm’s gross profit as reported stood at $3.63 billion against revenue of $9.44 billion.

Earnings Surprise

For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Analysts expected DGX to announce $2.87 per share in earnings in its latest quarter, but it posted $3.18, representing a 10.80% surprise. EBITDA for the quarter stood at more than $633.0 million. DGX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 6.92 billion, with total debt at $4.65 billion. Shareholders hold equity totaling $122.18 million

Technical Picture

Let’s look briefly at Quest Diagnostics Incorporated (DGX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 26.64% to suggest the stock is trending oversold, with historical volatility in this time period at 13.94%.

The stock’s 5-day moving average is $141.72, reflecting a -0.49% or -$0.69 change from its current price. DGX is currently trading -9.26% above its 20-day SMA, +6.87% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -1.79% and +16.84% respectively.

Stochastic %K and %D was 7.98% and 13.25% and the average true range (ATR) pointed at 2.77. The RSI (14) points at 31.07%, while the 14-day stochastic is at 5.44% with the period’s ATR at 2.75. The stock’s 9-day MACD Oscillator is pointing at -1.26 and -4.07 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Quest Diagnostics Incorporated (NYSE: DGX), UBS upgraded it to a Buy rating. They previously had a Neutral rating on the stock. Analysts offering their rating for DGX stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate DGX as a “sell,”, while 6 advise that investors “Hold.” 1 analysts have rated the stock as underweight. 1 rates the stock as overweight while 10 have offered a “buy” rating.

What is DGX’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $140.00 and a high of $181.00, with their median price target at $162.50. Looking at these predictions, the average price target given by analysts is for Quest Diagnostics Incorporated (DGX) stock is $160.00.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam